Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on C4 Therapeutics (CCCC – Research Report) today and set a price target ...
C4 Therapeutics (CCCC) announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback